Pharmaceutical sector giant BioAlliance Pharma received the patent for labial herpes drug, Sitavig from The United States Patent and Trademark Office (USPTO). This chemical patent is valid until 2027, for manufacturing and application processes of drug of recurrent labial herpes infection. 

BioAlliance Pharma is committed in developing oncological and orphan drugs, specifically to fight against drug resistance and rare diseases. 

According to Aude Michael, Vice president, licensing and legal affairs, ‘Sitavig received the patent from USPTO, in European countries and major Asian countries that protects our product worldwide’. 

The CEO of the company, Judith Greciet told that, the company received US registration file from Food and Drug Administration (FDA) on May, 2012 and this patent can commercially protect the product and its asset value. The company issued its first license to Israeli pharmaceutical company, Teva and expecting the sales of $120 to $150 million and Sitavig is a suitable drug for licensing agreement, particularly in United States of America.  

For years, BioAlliance Pharma developed Sitavig, for the treatment of labial herpetic infection, particularly in immunocompromised hosts. Sitavig is a mucoadhesive drug that contains anti-viral acyclovir, can be administered to labial herpetic patients by applying onto the upper gums. The drug exhibits increased absorption rate and efficacy, when administered at high doses, in herpetic infection site.